Fig 4. Comparison of the binomial and beta-binomial models of differential abundance and their ability to enrich for expanded TILs in the peripheral repertoire of responders to IO treatment.

(A) Percentage of expanded clones in the peripheral repertoire also found in the pre-treatment tumor repertoire, i.e., TILs, for a cohort of urothelial patients treated with atezolizumab (n = 26). Patients were categorized by RECIST outcomes as responders (CR/PR) or non-responders (SD/PD). (B) Percent change in the number of peripheral repertoire clones identified as expanded and the subset of circulating TIL clones expanded with the beta-binomial model relative to the binomial model. Error bars represent standard error of the mean.